Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization

Sci Rep. 2020 Jul 30;10(1):12827. doi: 10.1038/s41598-020-69744-y.

Abstract

Parkinson's disease (PD) and Alzheimer's disease (AD) are common neurodegenerative disorders of the elderly and, therefore, affect a growing number of patients worldwide. Both diseases share, as a common hallmark, the accumulation of characteristic protein aggregates, known as Lewy bodies (LB) in PD, and neurofibrillary tangles in AD. LBs are primarily composed of misfolded α-synuclein (aSyn), and neurofibrillary tangles are primarily composed of tau protein. Importantly, upon pathological evaluation, most AD and PD/Lewy body dementia cases exhibit mixed pathology, with the co-occurrence of both LB and neurofibrillary tangles, among other protein inclusions. Recent studies suggest that both aSyn and tau pathology can spread and propagate through neuronal connections. Therefore, it is important to investigate the mechanisms underlying aggregation and propagation of these proteins for the development of novel therapeutic strategies. Here, we assessed the effects of different pharmacological interventions on the aggregation and internalization of tau and aSyn. We found that anle138b and fulvic acid decrease aSyn and tau aggregation, that epigallocatechin gallate decreases aSyn aggregation, and that dynasore reduces tau internalization. Establishing the effects of small molecules with different chemical properties on the aggregation and spreading of aSyn and tau will be important for the development of future therapeutic interventions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / metabolism
  • Benzodioxoles / pharmacology*
  • Benzodioxoles / therapeutic use
  • Benzopyrans / pharmacology*
  • Benzopyrans / therapeutic use
  • Brain / metabolism
  • Catechin / analogs & derivatives*
  • Catechin / pharmacology
  • Catechin / therapeutic use
  • Cells, Cultured
  • Humans
  • Hydrazones / pharmacology*
  • Hydrazones / therapeutic use
  • Lewy Bodies / metabolism
  • Molecular Targeted Therapy
  • Neurofibrillary Tangles / metabolism
  • Parkinson Disease / drug therapy
  • Parkinson Disease / metabolism
  • Protein Aggregates / drug effects*
  • Protein Aggregation, Pathological / metabolism*
  • Pyrazoles / pharmacology*
  • Pyrazoles / therapeutic use
  • alpha-Synuclein / metabolism*
  • tau Proteins / metabolism*

Substances

  • 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole
  • Benzodioxoles
  • Benzopyrans
  • Hydrazones
  • N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
  • Protein Aggregates
  • Pyrazoles
  • alpha-Synuclein
  • tau Proteins
  • Catechin
  • gallocatechol
  • fulvic acid